A novel non-covalent inhibitor, WU-04, inhibits several mainstream coronaviruses and is a pan-inhibitor of 3CLpro.
The representative SARS-CoV-2 3CLpro inhibitors reported since 2020 and their biological activities and binding models are reviewed, providing new insights into the design and development of more effective 3CLpro inhibitors against SARS-CoV-2.
A novel antiviral and non-cytotoxic bioconjugate of tyrosinase from Agaricus bisporus (AbTyr)-dextran-aspartic acid (6 kDa) polymer is developed.
Identification of novel drug candidate with appropriate pharmacokinetic properties and drug-likeness for SARS-CoV-2.
DNA-encoded peptide covalent inhibitor library (DEPCIL) for discovering covalent inhibitors of protease and profiling active site preferences.